FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980455420> ?p ?o ?g. }

• W2980455420 abstract "Abstract Background Neuroblastoma is the most common extra-cranial solid tumor among children. Despite intensive treatment, patients with advanced disease mostly experience dismal outcomes. Here, we proposed the use of topotecan and cyclophosphamide containing induction regimen as an upfront therapy to high risk neuroblastoma patients. Methods Patients with high risk neuroblastoma undergoing ThaiPOG high risk neuroblastoma protocol from 2016 to 2017 were studied. All patients received 6 cycles of induction regimen consisting of 2 cycles topotecan (1.2 mg/m 2 /day) and cyclophosphamide (400 mg/m 2 /day) for 5 days followed by cisplatin (50 mg/m 2 /day) for 4 days combined with etoposide (200 mg/m 2 /day) for 3 days on the third and fifth cycles and cyclophosphamide (2100 mg/m 2 /day) for 2 days combined with doxorubicin (25 mg/m 2 /day) and vincristine (0.67 mg/m 2 /day) for 3 days on the fourth and sixth cycles. Treatment response after the 5th cycle before surgery and treatment-related toxicities after each topotecan containing induction cycle were evaluated. Relevant prognostic factors were analyzed to measure the treatment response among those patients. Results In all, 107 high risk neuroblastoma patients were enrolled in the study. After the 5th cycle of induction regimen, the patients achieved complete response ( N = 2), very good partial response ( N = 40), partial response ( N = 46) and mixed response ( N = 19). None of the patients experienced stable disease or disease progression. The most significant prognostic factor was type of healthcare system. The most common adverse effect was febrile neutropenia followed by mucositis, diarrhea and elevated renal function. Conclusion The topotecan and cyclophosphamide containing induction regimen effectively provides favorable treatment response. The regimen is well tolerated with minimal toxicity among patients with high risk neuroblastoma in Thailand." @default.
• W2980455420 created "2019-10-25" @default.
• W2980455420 creator A5010279227 @default.
• W2980455420 creator A5018720164 @default.
• W2980455420 creator A5027660444 @default.
• W2980455420 creator A5039244805 @default.
• W2980455420 creator A5042874753 @default.
• W2980455420 creator A5044701598 @default.
• W2980455420 creator A5049179921 @default.
• W2980455420 creator A5057073485 @default.
• W2980455420 creator A5062113126 @default.
• W2980455420 creator A5062943852 @default.
• W2980455420 creator A5074739571 @default.
• W2980455420 creator A5079891710 @default.
• W2980455420 creator A5080964667 @default.
• W2980455420 creator A5081007655 @default.
• W2980455420 creator A5087541392 @default.
• W2980455420 creator A5091823348 @default.
• W2980455420 date "2019-10-16" @default.
• W2980455420 modified "2023-09-25" @default.
• W2980455420 title "Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study" @default.
• W2980455420 cites W1901103115 @default.
• W2980455420 cites W1935226228 @default.
• W2980455420 cites W1962453771 @default.
• W2980455420 cites W1989989994 @default.
• W2980455420 cites W2024436666 @default.
• W2980455420 cites W2047547891 @default.
• W2980455420 cites W2057804172 @default.
• W2980455420 cites W2061454567 @default.
• W2980455420 cites W2068167166 @default.
• W2980455420 cites W2096398040 @default.
• W2980455420 cites W2097120541 @default.
• W2980455420 cites W2099669133 @default.
• W2980455420 cites W2110539841 @default.
• W2980455420 cites W2114441352 @default.
• W2980455420 cites W2120149213 @default.
• W2980455420 cites W2130593623 @default.
• W2980455420 cites W2130925781 @default.
• W2980455420 cites W2137648684 @default.
• W2980455420 cites W2139752108 @default.
• W2980455420 cites W2147800896 @default.
• W2980455420 cites W2148039277 @default.
• W2980455420 cites W2148768953 @default.
• W2980455420 cites W2150968555 @default.
• W2980455420 cites W2152420890 @default.
• W2980455420 cites W2164560906 @default.
• W2980455420 cites W2270855014 @default.
• W2980455420 cites W2496914699 @default.
• W2980455420 cites W2584822160 @default.
• W2980455420 cites W2589090458 @default.
• W2980455420 cites W2592061165 @default.
• W2980455420 cites W2593649209 @default.
• W2980455420 cites W2603739748 @default.
• W2980455420 cites W2611071372 @default.
• W2980455420 cites W2889489530 @default.
• W2980455420 cites W2899328567 @default.
• W2980455420 cites W2901513667 @default.
• W2980455420 cites W4211031423 @default.
• W2980455420 cites W4242436435 @default.
• W2980455420 cites W78311506 @default.
• W2980455420 doi "https://doi.org/10.1186/s12885-019-6186-z" @default.
• W2980455420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6796460" @default.
• W2980455420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31619207" @default.
• W2980455420 hasPublicationYear "2019" @default.
• W2980455420 type Work @default.
• W2980455420 sameAs 2980455420 @default.
• W2980455420 citedByCount "10" @default.
• W2980455420 countsByYear W29804554202021 @default.
• W2980455420 countsByYear W29804554202022 @default.
• W2980455420 crossrefType "journal-article" @default.
• W2980455420 hasAuthorship W2980455420A5010279227 @default.
• W2980455420 hasAuthorship W2980455420A5018720164 @default.
• W2980455420 hasAuthorship W2980455420A5027660444 @default.
• W2980455420 hasAuthorship W2980455420A5039244805 @default.
• W2980455420 hasAuthorship W2980455420A5042874753 @default.
• W2980455420 hasAuthorship W2980455420A5044701598 @default.
• W2980455420 hasAuthorship W2980455420A5049179921 @default.
• W2980455420 hasAuthorship W2980455420A5057073485 @default.
• W2980455420 hasAuthorship W2980455420A5062113126 @default.
• W2980455420 hasAuthorship W2980455420A5062943852 @default.
• W2980455420 hasAuthorship W2980455420A5074739571 @default.
• W2980455420 hasAuthorship W2980455420A5079891710 @default.
• W2980455420 hasAuthorship W2980455420A5080964667 @default.
• W2980455420 hasAuthorship W2980455420A5081007655 @default.
• W2980455420 hasAuthorship W2980455420A5087541392 @default.
• W2980455420 hasAuthorship W2980455420A5091823348 @default.
• W2980455420 hasBestOaLocation W29804554201 @default.
• W2980455420 hasConcept C126322002 @default.
• W2980455420 hasConcept C141071460 @default.
• W2980455420 hasConcept C143998085 @default.
• W2980455420 hasConcept C2776611710 @default.
• W2980455420 hasConcept C2776694085 @default.
• W2980455420 hasConcept C2776715637 @default.
• W2980455420 hasConcept C2776755627 @default.
• W2980455420 hasConcept C2778119113 @default.
• W2980455420 hasConcept C2779429289 @default.
• W2980455420 hasConcept C2781209748 @default.
• W2980455420 hasConcept C2781413609 @default.
• W2980455420 hasConcept C54355233 @default.
• W2980455420 hasConcept C71924100 @default.

• next